Merton G. Gollaher combines life-science experience with a talent for deal-making to help health care and technology clients compete in ever-changing markets. Trained as a chemist and with years of research experience as a molecular geneticist, Merton utilizes strong analytical thinking to resolve his client’s concerns and help build new affiliations, structure novel delivery networks, and nurture promising startups reshaping how health care is delivered.

Chambers USA described Merton as having a reputation for finding “creative solutions to complex problems.” He puts those skills to work specializing in business transactions, including mergers and acquisitions, affiliations and strategic alliances, financings, and joint ventures, as well as licensing and collaboration arrangements and other technology-transfer matters. He also devotes a significant portion of his practice to cultivating and counseling emerging growth companies spun out of universities and early-, mid-, and late-stage ventures in the biotechnology, life sciences, medical device, and health care IT industries.

Merton’s clients span a broad spectrum of disciplines, including life sciences, biotechnology, chemical and medical device companies, hospitals, health systems and other health care providers, and IT and manufacturing companies.
 
Before joining Garfunkel Wild, Merton was a partner at another law firm, where he was Chair of the Health Care Transactions Practice Group and Co-Chair of the Academic Medical Centers, Hospitals and Health Systems Practice Group. Prior to that, Merton was a research scientist at Pfizer, engaged in molecular genetics and protein chemistry research and in the application of computer-based modeling and imaging systems to these disciplines.